ADMA Biologics Stock Valuation


USD 3.32  0.09  2.79%   

Do you wonder what the value of ADMA Biologics is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as ADMA Biologics, is its stock price multiplied by the total number of shares outstanding, calculating ADMA Biologics' enterprise value requires a different approach. It uses ADMA Biologics' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
The current year Tangible Asset Value is expected to grow to about 292.4 M, whereas Free Cash Flow is forecasted to decline to (129.2 M).
ADMA Biologics shows a prevailing Real Value of $3.8 per share. The current price of the firm is $3.32. At this time, the firm appears to be undervalued. Our model approximates the value of ADMA Biologics from examining the firm fundamentals such as Profit Margin of (0.54) %, return on equity of (0.69) %, and Operating Margin of (0.36) % as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we favor taking in undervalued instruments and trading overvalued instruments since, in the future, asset prices and their ongoing real values will blend.
ADMA Biologics Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as ADMA Biologics's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Today 3.32
Please note that ADMA Biologics' price fluctuation is risky at this time. Calculation of the real value of ADMA Biologics is based on 3 months time horizon. Increasing ADMA Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for ADMA Biologics is useful when determining the fair value of the ADMA Biologics stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of ADMA Biologics. Since ADMA Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ADMA Biologics Stock. However, ADMA Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Real Value
Estimating the potential upside or downside of ADMA Biologics helps investors to forecast how ADMA Biologics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ADMA Biologics more accurately as focusing exclusively on ADMA Biologics' fundamentals will not take into account other important factors:
Estimates (4)
LowProjected EPSHigh
LowEstimated ValueHigh
LowNext ValueHigh
4 Analysts
LowTarget PriceHigh
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ADMA Biologics' intrinsic value based on its ongoing forecasts of ADMA Biologics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ADMA Biologics' closest peers. When choosing an evaluation method for ADMA Biologics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

ADMA Biologics Investments

6.06 Million

ADMA Biologics Valuation Drivers Correlation

Many accounts on the financial statements of ADMA Biologics are highly interrelated and sometimes correlated. Consequently, when conducting ADMA Biologics's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of ADMA Biologics
Click cells to compare fundamentals

ADMA Biologics Valuation Trend

Knowing ADMA Biologics' actual value is paramount for traders to make sound investment determinations. ADMA Biologics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of ADMA Biologics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both ADMA Biologics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

ADMA Biologics Market Cap

ADMA Biologics is number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is presently estimated at about 119.64 Billion. ADMA Biologics maintains roughly 635.59 Million in market capitalization contributing less than 1% to equities under Health Care industry.
Capitalization  Workforce  Total debt  Revenue  Valuation

ADMA Biologics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining ADMA Biologics's current stock value. Our valuation model uses many indicators to compare ADMA Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADMA Biologics competition to find correlations between indicators driving ADMA Biologics's intrinsic value. More Info.
ADMA Biologics is number one stock in price to book category among related companies. It is number one stock in beta category among related companies totaling about  0.16  of Beta per Price to Book. The ratio of Price to Book to Beta for ADMA Biologics is roughly  6.37 . Comparative valuation analysis is a catch-all model that can be used if you cannot value ADMA Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ADMA Biologics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADMA Biologics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ADMA Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ADMA Biologics and how it compares across the competition.

About ADMA Biologics Valuation

The stock valuation mechanism determines the current worth of ADMA Biologics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of ADMA Biologics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of ADMA Biologics based exclusively on its fundamental and basic technical indicators. By analyzing ADMA Biologics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of ADMA Biologics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of ADMA Biologics. We calculate exposure to ADMA Biologics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to ADMA Biologics's related companies.
Last ReportedProjected for 2022
Gross Profit1.2 M1.3 M
Profit Margin(79.66) (85.95) 

ADMA Biologics Current Valuation Indicators

Valuation refers to the process of determining the present value of ADMA Biologics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ADMA Biologics we look at many different elements of the entity such as ADMA Biologics's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. ADMA Biologics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ADMA Biologics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ADMA Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ADMA Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ADMA Biologics' worth.
Please continue to Trending Equities. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.